highdose melphalan regimens to overcome resistance to both standard melphalan-prednisone and VAD, enhancing the incidence of complete remission from less than 5 percent into the 50 percent range with the use of tandem transplants as the primary management of newly diagnosed patients. He and his colleagues also pioneered this dose intensity approach in the setting of renal failure, a frequent complication of multiple myeloma. A third fundamental contribution to myeloma therapy was the demonstration of major activity of thalidomide in far-advanced myeloma relapsing after tandem transplants.

Dr. Barlogie was educated in Germany and earned his medical degree from Heidelberg University. Following residency training at the Universities of Munich and Muenster, he joined the University of Texas M.D. Anderson Hospital and Tumor Research Institute in 1974 where he worked under Emil J. Freireich and colleagues in developmental therapeutics. Eventually, he chaired the Department of Hematology.

He became director of hematology/oncology and research at the Arkansas Cancer Research Center (ACRC) at UAMS in 1989. He subsequently became director of the cancer research center and then director of the new Myeloma Institute in 2001.

Dr. Barlogie's pioneering work has stimulated confirmatory trials worldwide. More so than any other myeloma investigator, Dr. Barlogie challenged the conventional approach of disease palliation and radically pursued the cure concept by treatment approaches aimed at increasing the incidence of complete remission as a first critical step toward that goal. In essence, he applied the lessons he was able to learn from clinical trial investigations in acute leukemia to the myeloma problem. Dr. Barlogie's work has been published in leading peer-reviewed medical journals, and he recently received the prestigious Waldenstrom Award for Myeloma Research.